(52 days)
No
The description focuses on the mechanical and thermal aspects of the device for cryoablation and does not mention any AI/ML components or functions.
Yes
The device is described as "intended for use in blocking pain by temporarily ablating peripheral nerves," which is a therapeutic action.
No
The device description indicates its use for "temporarily freeze the tissue in contact with the probe tip by circulating a cryogenic agent, nitrous oxide, through the device," which is a treatment (ablation) function, not a diagnostic one.
No
The device description clearly describes a physical probe and its interaction with a Cryo Module, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "blocking pain by temporarily ablating peripheral nerves." This is a therapeutic procedure performed directly on the patient's body.
- Device Description: The device is a probe used to freeze tissue in contact with the tip. This is a physical intervention, not a test performed on a sample taken from the body.
- Lack of IVD Characteristics: The description does not mention analyzing samples (like blood, urine, tissue), detecting substances, or providing diagnostic information about a patient's condition.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
AtriCure's cryoICE cryoSPHERE cryoablation probes are sterile, single use devices intended for use in blocking pain by temporarily ablating peripheral nerves.
Product codes (comma separated list FDA assigned to the subject device)
GXH
Device Description
The cryoICE cryoSPHERE cryoablation (CRYOS) probe is a single use device that achieves cryoablation of peripheral nerves by allowing a surgeon to insert the probe through an incision to reach the target tissue, place the probe tip on the target site, and in conjunction with an AtriCure Cryo Module (ACM), temporarily freeze the tissue in contact with the probe tip by circulating a cryogenic agent, nitrous oxide, through the device. The CRYOS probe is offered in two probe length configurations: approximately 11" and 18" long. The probe is malleable, and is capable of being bent by the end user. At the distal end, the CRYOS device features an 8 mm diameter ball tip shaped probe.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
peripheral nerves
Indicated Patient Age Range
Not Found
Intended User / Care Setting
surgeon
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following bench testing was conducted for design and performance elements deemed appropriate to demonstrate equivalence to the previously cleared CRYO2 device met the predetermined acceptance criteria ensuring substantial equivalence to the previously cleared CRYO2 device. No new safety or performance issues were raising during testing.
Non-clinical Bench Testing:
- Reliability Testing
- Transit
- Shelf-life
- Cryogen Performance/Thermal Insulation
- Mechanical testing
- Biocompatibility
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.4250 Cryogenic surgical device.
(a)
Identification. A cryogenic surgical device is a device used to destroy nervous tissue or produce lesions in nervous tissue by the application of extreme cold to the selected site.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. Food & Drug Administration" in blue.
November 9, 2018
AtriCure, Inc. Jonathan McElwee Regulatory Affairs Manager 7555 Innovation Way Mason, Ohio 45040
Re: K182565
Trade/Device Name: AtriCure cryoICE cryoSPHERE cryoablation probe Regulation Number: 21 CFR 882.4250 Regulation Name: Cryogenic Surgical Device Regulatory Class: Class II Product Code: GXH Dated: September 17, 2018 Received: September 18, 2018
Dear Jonathan McElwee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be avare that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Matthew C. Krueger -S
for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K182565
Device Name cryoICE® cryoSPHERE™ cryoablation probe
Indications for Use (Describe)
AtriCure's cryolCE cryoSPHERE cryoablation probes are sterile, single use devices intended for use in blocking pain by temporarily ablating peripheral nerves.
Type of Use (Select one or both, as applicable) | |
---|---|
X | Prescription Use (Part 21 CFR 801 Subpart D)
| | Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/1 description: The image shows the word "AtriCure" in a stylized font. The first three letters, "Atri", are in blue, while the rest of the word, "Cure", is in orange. The "C" in "Cure" has a blue dot in the middle. There is a registered trademark symbol to the right of the word.
510(k) Summary
l. Applicant Information
| Manufacturer: | AtriCure®, Inc.
7555 Innovation Way
Mason, Ohio 45040
P: 513-644-4736
F: 513-895-9013 |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Jonathan McElwee, RAC
Manager, Regulatory Affairs |
| Date Prepared: | 9/17/2018 |
| II.
Device Information | |
| Proprietary Name: | cryoICE™ cryoSPHERE® cryo-ablation probe (CRYOS) |
| Common Name: | Cryosurgical Probe |
| Classification: | Cryogenic surgical device
Regulatory Class: Class II; per 21 CFR 882.4250
Product Code: GXH
Classification Panel: Neurodiagnostic and Neurosurgical Devices |
| Predicate Device: | cryoICE cryoablation probe (CRYO2)
(K180138, February 15, 2018) |
| Reference Device: | cryoICE cryoablation probe (CRYO2)
(K142203, November 25, 2014) |
III. Device Description
The cryolCE cryoSPHERE cryoablation (CRYOS) probe is a single use device that achieves cryoablation of peripheral nerves by allowing a surgeon to insert the probe through an incision to reach the target tissue, place the probe tip on the target site, and in conjunction with an AtriCure Cryo Module (ACM), temporarily freeze the tissue in contact with the probe tip by circulating a cryogenic agent, nitrous oxide, through the device. The CRYOS probe is offered in two probe length configurations: approximately 11" and 18" long. The probe is malleable, and is capable of being bent by the end user. At the distal end, the CRYOS device features an 8 mm diameter ball tip shaped probe.
IV. Intended Use/ Indications for Use
AtriCure's cryolCE cryoSPHERE cryoablation probes are sterile, single use devices intended for use blocking pain by temporarily ablating peripheral nerves.
4
AtriCure®
Comparison of Technological Characteristics (CRYO2 K180138) V.
- The devices include the same intended use, and; ●
- No changes were made in operating principle, or specifications of performance, and; .
- The results of the verification and validation testing: .
- o Demonstrated equivalency in performance
- O Did not raise any new issues of safety
Modifications included in the cryoSPHERE probe end-effector were for differing body habitus and surgeon preference for the use of the device specifically intended to blocking pain.
CRYO2 (Predicate) | CRYOS (Subject) | |
---|---|---|
Market Product | ||
Name | cryoICE cryoablation probe | cryoICE cryoSPHERE cryoablation probe |
510(k) Number | K180138 | Subject of this Submission |
Intended Use | AtriCure's cryoICE cryo-ablation probes are | |
sterile, single use devices intended for use in the | ||
cryosurgical treatment of cardiac arrhythmias by | ||
freezing target tissues, creating an inflammatory | ||
response (cryonecrosis) that blocks the electrical | ||
conduction pathway. The probe is also intended | ||
for use in blocking pain by temporarily ablating | ||
peripheral nerves. | AtriCure's cryolCE cryoSPHERE cryoablation | |
probes are sterile, single use devices intended | ||
for use blocking pain by temporarily ablating | ||
peripheral nerves. | ||
Operating | ||
Principle | Joule-Thompson Effect | Joule-Thompson Effect |
Technology | The system consists of cryoprobes that are used | |
for freezing target tissue. A console is used to | ||
control the supply of gas to the cryoprobe. | The system consists of cryoprobes that are used | |
for freezing target tissue. A console is used to | ||
control the supply of gas to the cryoprobe. | ||
Energy Used | Nitrous Oxide | Nitrous Oxide |
Operating | ||
Temperature | -50°C to 70°C | -50°C to 70°C |
Human Factors | Hand-held device containing cryogen with | |
activation button on console or footswitch. | Hand-held device containing cryogen with | |
activation button on console or footswitch. | ||
Cryotip | Material: aluminum alloy | Material: aluminum alloy |
Construction: smooth malleable cylindrical linear | ||
probe | Construction: smooth spherical ball welded to a | |
malleable cylindrical aluminum shaft. | ||
Diameter: 4 mm | Diameter: ball - 8mm; aluminum shaft - 5mm | |
Length: 10cm | Length: reference the "end-effector" length | |
End-effector | ||
Length – Shaft | ||
and Cryotip | 28 cm | 28cm (CRYOS) |
46cm (CRYOS-L) | ||
Biocompatibility | Biocompatible patient contacting materials. | Biocompatible patient contacting materials. |
Probe Packaging | Sterile - Single Use disposable device | Sterile - Single Use disposable device |
Sterilization | Gamma Irradiation | Gamma Irradiation |
Power Source | Mains Powered | Mains Powered |
5
VI. Performance Data
The following bench testing was conducted for design and performance elements deemed appropriate to demonstrate equivalence to the previously cleared CRYO2 device met the predetermined acceptance criteria ensuring substantial equivalence to the previously cleared CRYO2 device. No new safety or performance issues were raising during testing.
Non-clinical Bench Testing:
- Reliability Testing ●
- Transit ●
- Shelf-life
- Cryogen Performance/Thermal Insulation ●
- Mechanical testing .
- Biocompatibility .
VII. Conclusions
AtriCure has demonstrated that the cryolCE cryoSPHERE cryoablation probe is substantially equivalent in fundamental design, technology, function, device materials, packaging, sterilization, operating principal, and intended use/ indication for use as the previously cleared device: cryolCE cryoablation probe.